Clinical Trials
124 trialsNCT04320888 2026-05-27
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439149 2026-05-27
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439188 2026-05-27
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07524530 2026-05-27
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Not yet recruiting
NCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03258567 2026-05-22
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04439292 2026-05-19
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06385496 2026-05-13
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06390865 2026-05-13
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06400225 2026-05-13
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06400251 2026-05-11
Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439110 2026-05-08
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439266 2026-05-07
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439279 2026-05-07
Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439331 2026-05-07
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439344 2026-05-07
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439123 2026-05-06
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439175 2026-05-06
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06357988 2026-05-06
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05490771 2026-05-05
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06390852 2026-05-05
Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06400238 2026-05-05
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439227 2026-05-04
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06360575 2026-05-04
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439136 2026-04-29
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439253 2026-04-29
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06390826 2026-04-29
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06385483 2026-04-23
Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439201 2026-04-13
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439318 2026-04-13
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439357 2026-04-13
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06303167 2026-04-13
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06308822 2026-04-13
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06390839 2026-04-13
Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06357975 2026-03-19
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT00001379 2025-06-19
Treatment and Natural History Study of Lymphomatoid Granulomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02631746 2025-03-14
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT04847050 2024-08-27
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT06400264 2024-05-06
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT03255018 2023-11-28
Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00114738 2022-10-10
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00069238 2022-02-24
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00051311 2021-09-09
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT04439240 2021-06-29
Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)
National Cancer Institute (NCI)
Phase 2 Completed
NCT04439214 2021-04-06
Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)
National Cancer Institute (NCI)
Phase 2 Completed
NCT04439305 2020-07-20
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00074490 2018-12-31
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00080535 2018-01-29
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00082017 2017-05-15
UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00025662 2016-10-28
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
National Institutes of Health Clinical Center (CC)
Phase 2 Completed